BOTHELL, Wash.--(BUSINESS WIRE)--Plexera Bioscience LLC, a wholly owned subsidiary of Lumera Corporation (NASDAQ:LMRA), and MitoSciences Inc., developers of antibodies and assays for understanding mitochondrial function, announced today that they have entered into an agreement that outlines a commercial path for an antibody array product which is enabled with Plexera’s ProteomicProcessor™ and MitoSciences’ proprietary antibodies. This product development is in conjunction with a separate and previously announced agreement with the Medical University of South Carolina in which researchers there are building a protein expression profiling assay with Mitosciences’ antibodies and Plexera’s ProteomicProcessor™.
